Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: A randomized, double-blind, placebo-controlled study

Blood Coagulation and Fibrinolysis

Volumn 16, Issue 8, 2005, Pages 549-555

  Chuansumrit, Ampaiwan ^a   Wangruangsatid, Somporn ^b   Lektrakul, Yujinda ^c   Chua, Mary Ng ^d   Capeding, Maria Rosario Zeta ^e   Bech, Ole Molskov ^f  

^a MAHIDOL UNIVERSITY   (Thailand)

^b BUDDHACHINARAJ HOSPITAL   (Thailand)

^c Sappasitthiprasong Hospital   (Thailand)

^d UNIVERSITY OF SANTO TOMAS   (Philippines)

^e Research Institute for Tropical Medicine   (Philippines)

^f Novo Nordisk Pharma Singapore Pte Ltd   (Singapore)

Author keywords

Activated factor VII; Bleeding; Dengue hemorrhagic fever; Efficacy

Indexed keywords

PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOCYTE CONCENTRATE;

ABNORMAL RESPIRATORY SOUND; ADOLESCENT; ARTICLE; BLEEDING DISORDER; BLOOD COMPONENT THERAPY; BODY WEIGHT; BOLUS INJECTION; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DENGUE; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECCHYMOSIS; EPISTAXIS; ERYTHROCYTE; FEMALE; GINGIVA BLEEDING; HEMATEMESIS; HEMATOCHEZIA; HEMATURIA; HUMAN; HYPERMENORRHEA; MALE; MELENA; PETECHIA; PLEURA EFFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

EID: 27844454825     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000186837.78432.2f     Document Type: Article

References (25)

1. Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 1998; 19:163-176.
2. Hedner U. Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000. Semin Thromb Hemost 2000; 26:363-366.
3. Roberts HR, Monroe DM, Escobar MA. Current concepts of hemostasis: implications for therapy. Anesthesiology 2004; 100:722-730.
4. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 2000; 26:425-432.
5. Niikura T, Nishikawa T, Saegusa Y, Fujishiro T, Yoshiya S, Kurosaka M. Total hip arthroplasty in severe congenital factor VII deficiency. J Arthroplasty 2005; 20:396-400.
6. Kubisz P, Stasko J. Recombinant activated factor VII in patients at high risk of bleeding. Hematology (Netherlands) 2004; 9:317-332.
7. He S, Ekman GJ, Hedner U. The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia. J Thromb Hemost 2005; 3:272-279.
8. Al Douri M, Shafi T, Al Khudairi D, Al Bokhari E, Black L, Akinwale N, et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000; 11(Suppl 1):S121-S127.
9. Vlot AJ, Ton E, Mackay AJ, Kramer MH, Gaillard CA. Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII. Am J Med 2000; 108:421-423.
10. Friederich PW, Henny CP, Messelink EJ, Mark GG, Keller T, Kurth KH, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361:201-205.
11. Goodnough LT. Treatment of critical bleeding in the future intensive care unit. Intensive Care Med 2002; 28:S221.
12. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352:777-785.
13. Levi M, Peters M, Büller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33:883-890.
14. Deveras RAE, Kessler CM. Reversal of warfarin induced excessive anticoagulation with recombinant factor VIIa concentrate. Ann Intern Med 2002; 137:884-888.
15. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003; 14:469-477.
16. World Health Organization. Dengue hemorrhagic fever: diagnosis, treatment and control, 2nd ed. Geneva: WHO Geneva Publication; 1997, pp. 12-23.
17. World Health Organization. Dengue/dengue haemorrhagic fever. Weekly Epidemiological Record 2000; 75:193-196.
18. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. 52nd WMA General Assembly; October 2000; Edinburgh, UK. Last amended with Note of Clarification on Paragraph 29 by Washington: WMA General Assembly; 2002.
19. Ramathibodi Clinical Practice Guideline. Dengue hemorrhagic fever. In: Benjaponpitak S, Wanitkum S, Tangnararatchakit K, Chantanarojanasiri T, Suwanjutha S, editors: Pediatric critical care, 2nd ed. Bangkok: Bejorn Enterprise; 2002, pp. 253-260.
20. Mitrakul C, Poshyachinda M, Futrakul P, Sangkawibha N, Ahandrik S. Hemostatic and platelet kinetic studies in dengue hemorrhagic fever. Am J Trop Med Hyg 1977; 26:975-984.
21. Isarangkura PB, Pongpanich B, Pintadit P, Phanichayakarn P, Valayasevi A. Hemostatic derangement in dengue hemorrhagic fever. Southeast Asian J Trop Med Public Health 1987; 18:331-339.
22. 3 and fibrinogen degradation product in Thai hemorrhagic fever. J Med Assoc Thai 1973; 56:24-32.
23. Willis BA, Oragui EE, Stephens AC, Daramola OA, Dung NM, Loan HT, et al. Coagulation abnormalities in dengue hemorrhagic fever: serial investigations in 167 Vietnam children with dengue shock syndrome. Clin Infect Dis 2002; 35:277-285.
24. Krishnamurit C, Kalayanarooj S, Cutting MA, Peat RA, Rothwell SW, Peid TJ, et al. Mechanism of hemorrhage in dengue without circulatory collapse. Am J Trop Med Hyg 2001; 65:840-847.
25. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost 2000; 26:385-391.